The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient DNA mismatch repair (dMMR) colon cancer significantly improved survival in the phase 3 ATOMIC trial.

“These data established this combination as a new standard treatment for patients with stage III colon cancer and deficient mismatch repair,” said study author Frank A. Sinicrope, MD, during a press conference at the American Society of Clinical Oncology (ASCO) 2025 annual meeting. “We regard this as a highly impactful study that will change clinical practice, and it actually represents the first immunotherapy adjuvant study in colon cancer.”

The standard treatment for stage III colon cancer, regardless of dMMR status, is surgical resection followed by fluoropyri

See Full Page